UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 20-F
(Amendment No. 1)
(Mark One)
[ ]
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
[X]
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended
April 30, 2005
OR
[ ]
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________________ to ____________________
[ ]
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report…………………….
Commission file number
0-22966
MIGENIX Inc.
(Exact name of Registrant as specified in its charter)
British Columbia, Canada
(Jurisdiction of incorporation or organization)
3650 Wesbrook Mall, Vancouver, B.C., Canada V6S 2L2
(Address of principal executive offices)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each Class |
| Name of each exchange on which registered |
None |
|
|
Securities registered or to be registered pursuant to Section 12(g) of the Act:
Common Shares, without par value
(Title of Class)
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:
Not Applicable
(Title of Class)
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by this annual report:
60,988,428 Common Shares
350,000 Series A Preferred Shares
1,000,000 Series B Preferred Shares
5,250,000 Series C Preferred Shares
4,000,000 Series D Preferred Shares
4,000,000 Series E Preferred Shares
1
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes X
No _____
Indicate by check mark which financial statement item the registrant has elected to follow.
Item 17 ____
Item 18 X
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ____
No X
2
EXPLANARY NOTE
This Amendment No. 1 on Form 20-F/A (the "Amendment No. 1") amends the Annual Report on Form 20-F for the year ended April 30, 2005 filed on October 31, 2005 (the "Original Filing"). MIGENIX Inc. has filed this Form 20-F solely for the purpose of adding Exhibit A to Exhibit 4.33. We hereby replace the Exhibit 4.33 of the Original Filing with the amended Exhibit 4.33 included in this Amendment No. 1.
Except for the foregoing, this Amendment No. 1 (i) does not amend, update or restate any information from that contained in the Original Filing and (ii) speaks only as of the filing date of the Original Filing and does not purport to reflect events or developments subsequent to the filing date of the Original Filing. Accordingly, you should read this Amendment No. 1 together with the Original Filing and other documents that we have filed with and furnished to the Canadian securities regulators and the U.S. Securities and Exchange Commission subsequent to the filing date of the Original Filing. Information in such reports and documents updates and supersedes certain information contained in the Original Filing and this Amendment No. 1. The filing of this Amendment No. 1 shall not be deemed an admission that the Original Filing, when made, included any known, untrue statement of material fact or knowingly omitted to state a material fact necessary to ma ke a statement not misleading.
ITEM 19. EXHIBITS
The list of Exhibits filed as part of this annual report are set forth on the Exhibit Index immediately preceding such Exhibits, and is incorporated herein by this reference.
3
SIGNATURES
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Company certifies that it meets all of the requirements for filing on Form 20-F and has duly caused and authorized the undersigned to sign this amendment to its annual report on its behalf.
|
|
| MIGENIX Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
Dated: | January 15, 2007 | By: | “James M. DeMesa” |
|
|
| James M. DeMesa |
|
|
| President and Chief Executive Officer |
|
|
|
|
|
|
|
|
|
|
|
|
Dated: | January 15, 2007 | By: | “Arthur J. Ayres” |
|
|
| Arthur J. Ayres |
|
|
| Senior Vice President Finance, Chief Financial Officer |
|
|
|
|
|
|
|
|
4
EXHIBIT INDEX
Exhibit Number | Description |
|
1.1 | Articles as amended September 8, 2004* | (7) |
2.1 | Shareholder Rights Plan dated July 31, 2000 between the Company and Pacific Corporate Trust Company. | (4) |
4.1 | Premises License Agreement dated March 7, 1995 between the Company and B.C. Research Inc. | (1) |
4.2 | License Agreement dated October 19, 1995 between the Company and The University of British Columbia | (1) |
4.3 | 1996 Incentive Stock Option Plan effective February 9, 1996 | (2) |
4.4 | Amended and Restated Escrow Agreement dated October 22, 1998 between Pacific Corporate Trust Company, the Company, William W. Kay, Kevin Nephin, Robert Hancock, Heidi Hirst and Steve Elliston | (3) |
4.5 | Micrologix 2000 Incentive Stock Option Plan effective July 31, 2000. | (4) |
4.6 | Amended Collaborative Research and License Agreement with BioSource Pharm, Inc. dated May 17, 2002* | (5) |
4.7 | Stock Purchase Agreement with BioSource Pharm, Inc. dated May 20, 2002* | (5) |
4.8 | Asset Purchase Agreement with IntraBiotics Pharmaceuticals Inc. dated May 20, 2002* | (5) |
4.9 | Stock Purchase Agreement with IntraBiotics Pharmaceuticals Inc. dated May 20, 2002* | (5) |
4.10 | Collaboration and License Agreement with Fujisawa Healthcare Inc. dated July 8, 2002* | (5) |
4.11 | Collaboration and License Agreement with Hybridon Inc. dated September 11, 2002* | (5) |
4.12 | Executive Employment Agreement with James M. DeMesa dated as of October 1, 2001 | (5) |
4.13 | License Agreement dated February 2, 2004 with Virogen Limited in respect of the acquisition of the Celgosivir drug development program.* | (7) |
5
4.14 | Stock Purchase Agreement with Hybridon, Inc. dated December 17, 2002 in respect of 5,500,000 Series C Preferred Shares issued to Hybridon in connection with a Collaboration and License Agreement.* | (6) |
|
4.15 | First amendment (January 31, 2003) to Executive Employment agreement dated October 1, 2001 with James M. DeMesa. | (6) |
|
4.16 | Second amendment (June 2, 2003) to Executive Employment agreement dated October 1, 2001 with James M. DeMesa. | (6) |
|
4.17 | Third amendment (September 1, 2003) to Executive Employment agreement dated October 1, 2001 with James M. DeMesa. |
|
|
4.18 | Form of Vice President Employment Agreements. | (6) |
|
4.19 | Stock Purchase Agreement with Virogen Limited dated February 20, 2004 in respect of 4,100,000 Series D Preferred Shares issued to Virogen in connection with the License Agreement.* | (7) |
|
4.20 | License Agreement dated December 8, 2003 with Spring Bank Technologies, Inc. for the out-license of a HBV compound.* | (7) |
|
4.21 | Stock Purchase Agreement with Spring Bank Technologies, Inc. dated December 17, 2003 in respect of 4,000 Series A Preferred Shares received by Spring Bank in connection with the License Agreement.* | (7) |
|
4.22 | Agreement and Plan of Merger and Reorganization with Mitokor, Inc. dated April 15, 2004.* | (7) |
|
4.23 | Exchange and Escrow Agreement in relation to Agreement and Plan of Merger and Reorganization with Mitokor, Inc.* | (7) |
|
4.24 | Collaboration and License Agreement with Strata Pharmaceuticals, Inc. dated August 2, 2004 for the co-development and commercialization of MX-226.* | (7) |
|
4.25 | Stock Purchase Agreement with Strata Pharmaceuticals, Inc. dated August 2, 2004 in connection with the Collaboration and License Agreement. | (7) |
|
4.26 | License and Option Agreement dated February 8, 1999 by and between Apollo BioPharmaceutics, Inc. and American Home Products Corporation acting through its Wyeth-Ayerst Laboratories Division |
|
|
4.27 | License and Royalty Agreement dated November 4, 1998 by and between MitoKor, Inc. and Pfizer Inc. |
|
|
4.28 | Patent License Agreement with Research Component dated February 4, 1999 by and between Apollo BioPharmaceutics Inc. and University of Florida Research Foundation.* |
|
|
4.29 | License Agreement with Washington University dated March 21, 2005.* |
|
|
4.30 | Investment Agreement with Technology Partnerships Canada dated March 31, 2005 for the development of MX-2401.* |
|
|
4.31 | Agency Agreement with Canaccord Capital and other agents dated May 18, 2005 in connection with the May 31, 2005 financing. |
|
|
4.32 |
|
|
6
4.33 | Material Transfer and License Option Agreement with Schering Corporation dated July 13, 2005 for MX-3253.* |
|
|
8.1 | List of significant subsidiaries and jurisdiction of incorporation. |
|
|
12.1 |
|
| |
12.2 |
|
| |
13.1 |
|
| |
13.2 |
|
|
(1)
Incorporated by reference to Exhibits filed as part of the Registrant’s Annual Report on Form 20-F for the Fiscal Year ended April 30, 1995 filed with the Securities and Exchange Commission on October 30, 1995.
(2)
Incorporated by reference to Exhibits filed as part of the Registrant’s Annual Report on Form 20-F for the Fiscal Year ended April 30, 1996 filed with the Securities and Exchange Commission on October 30, 1996.
(3)
Incorporated by reference to the Exhibits filed as part of the Registrant’s Annual Report on Form 20-F for the Fiscal Year ended April 30, 1999 filed with the Securities and Exchange Commission on September 20, 1999.
(4)
Incorporated by reference to the Exhibits filed as part of the Registrant’s Annual Report on Form 20-F for the Fiscal Year ended April 30, 2000 filed with the Securities and Exchange Commission on September 25, 2000.
(5)
Incorporated by reference to the Exhibits filed as part of the Registrant’s Annual Report on Form 20-F for the Fiscal Year ended April 30, 2002 filed with the Securities and Exchange Commission on October 30, 2002.
(6)
Incorporated by reference to the Exhibits filed as part of the Registrant’s Annual Report on Form 20-F for the Fiscal Year ended April 30, 2003 filed with the Securities and Exchange Commission on September 17, 2003.
(7)
Incorporated by reference to the Exhibits filed as part of the Registrant’s Annual Report on Form 20-F for the Fiscal Year ended April 30, 2004 filed with the Securities and Exchange Commission on September 30, 2004.
* The Company has requested confidential treatment with respect to certain portions of this Agreement, which have been omitted, pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
7
